ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: L13

Anifrolumab Long-Term Treatment Is More Effective Against Organ Damage Than Standard of Care Alone: Results from an External Control Arm Study on Organ Damage in Phase 3 Clinical Trials and the University of Toronto Lupus Clinic Cohort

Zahi Touma1, Ian Bruce2, Richard A. Furie3, Eric Morand4, Raj Tummala5, Shelly Chandran6, Gabriel Abreu7, Jacob Knagenhjelm7, Kellyn Arnold8, Hopin Lee8, Eleanor Ralphs8, Danuta Kielar9, Aleksander Bedenkov9 and Miina Waratani9, 1Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, 2Queen's University Belfast, Belfast, United Kingdom, 3Northwell Health, Manhasset, NY, 4Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, 5BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 6Astrazeneca, Mississauga, ON, Canada, 7BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 8IQVIA, London, United Kingdom, 9Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom

Meeting: ACR Convergence 2024

Date of first publication: October 24, 2024

Keywords: Biologicals, Damage Index, Late-Breaking 2024, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: (L01–L14) Late-Breaking Posters

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: In SLE, persistent disease activity, disease flares and long-term glucocorticoid (GC) use all contribute to organ damage accrual. The effects of novel therapies on this trajectory are challenging to evaluate in clinical trials due to attrition of patients receiving SOC and limited study duration. The LASER study (NCT06485674) is an external control arm study assessing the effects of anifrolumab versus SOC on accumulation of long-term organ damage in patients with active SLE.

Methods: Patients assigned to anifrolumab 300 mg in the TULIP-1/-2 trials1 were included in the anifrolumab arm (n=354). The external control (SOC) arm included biologic-naïve patients from the University of Toronto Lupus Clinic (UTLC) cohort who matched key eligibility criteria from TULIP (n=561). Propensity score methods and censoring weighting were used to account for baseline confounding and loss to follow-up. Fourteen known predictors of organ damage were included in the propensity score model (Table). Treatment arms were considered balanced on a covariate if the standardized mean difference in propensity score was ≤0.2. The primary endpoint assessed the mean difference in SLICC/ACR Damage Index (SDI) changes from baseline at year 4 between the two arms, and the average treatment effect in the control group (ATC) was estimated using the SOC arm as the target group. Average treatment effect in the treated group (ATT) and 1:1 propensity score matching (PSM) were performed as sensitivity analyses. The secondary endpoint compared time to first organ damage (SDI) progression and was estimated in the ATC sample through Cox regression. SLEDAI-2K score and proteinuria remained unbalanced, and were included in the Cox regression model. ATC, ATT, and PSM data are mean (95% confidence interval [CI]) change in SDI.

Results: All analyses indicated a greater increase in SDI with SOC compared with the anifrolumab arm after 4 years. In the ATC analysis (TULIP, n=354; UTLC, n=561), the mean (95% CI) change in SDI was 0.162 (0.046─0.279) with anifrolumab and 0.587 (0.479─0.695) with SOC; mean difference -0.416; P< 0.0001. In the ATT analysis (TULIP, n=354; UTLC, n=561), the mean (95% CI) change in SDI was 0.224 (0.149–0.299) with anifrolumab and 0.561 (0.390–0.733) with SOC; mean difference -0.337; P< 0.0001. The PSM (both TULIP and UTLC n=116) mean (95% CI) change in SDI was 0.201 (0.119–0.283) and 0.571 (0.380–0.761) in the anifrolumab and SOC arms; mean difference –0.370; P=0.002. Patients in the anifrolumab arm had 59.9% lower risk of first SDI progression over 48 months compared with SOC (hazard ratio=0.401; [95% CI: 0.213–0.753]; P<0.01) (Figure).

Conclusion: Our study suggests that long-term anifrolumab treatment may delay the onset of irreversible organ damage and reduce the rate of damage accrual in patients with moderate to severe SLE. The known benefits of anifrolumab in controlling disease activity, reducing flares, and reducing oral GC use in patients with SLE may help explain this observation.

Kalunian K, et al. Arthritis Rheumatol. 2023;75(2):253-265.

Supporting image 1

Supporting image 2


Disclosures: Z. Touma: AstraZeneca, 1, GlaxoSmithKline Inc., 2, Merck KgaA, 2, Novartis, 1, Roche, 2, Sarkana Pharma Inc., 2, UCB Biopharma, 1, 2; I. Bruce: AstraZenaca, 2, 5, 6, Dragonfly Therapeutics, 2, GSK, 2, 6, Janssen, 2, 5, 6, Lilly, 2, Takeda, 2; R. Furie: AstraZeneca, 1, 2, 6, Genentech, 2, 5, GlaxoSmithKlein(GSK), 2, 5; E. Morand: AbbVie, 2, 5, Amgen, 5, AstraZeneca, 2, 5, 6, 12, Paid instructor, Biogen, 2, 5, BMS, 2, 5, 6, Dragonfly, 2, Eli Lilly, 2, 5, EMD Serono, 2, 5, Genentech, 5, GSK, 2, 5, Janssen, 5, Novartis, 2, 5, Remegen, 2, Roche, 6, Takeda, 2, 5, UCB, 2, 5; R. Tummala: AstraZeneca, 3; S. Chandran: Abbvie, 2, 5, 6, AstraZeneca, 3, BMS, 2, 6, EliLilly, 2, 6, Fresenius Kabi, 2, 6, Janssen, 2, 6, Novartis, 2, 6, UCB, 2, 6; G. Abreu: AstraZeneca, 3; J. Knagenhjelm: AstraZeneca, 3, 11; K. Arnold: IQVIA, 3; H. Lee: None; E. Ralphs: IQVIA, 7; D. Kielar: AstraZeneca, 3, 11; A. Bedenkov: AstraZeneca, 3; M. Waratani: AstraZeneca, 3.

To cite this abstract in AMA style:

Touma Z, Bruce I, Furie R, Morand E, Tummala R, Chandran S, Abreu G, Knagenhjelm J, Arnold K, Lee H, Ralphs E, Kielar D, Bedenkov A, Waratani M. Anifrolumab Long-Term Treatment Is More Effective Against Organ Damage Than Standard of Care Alone: Results from an External Control Arm Study on Organ Damage in Phase 3 Clinical Trials and the University of Toronto Lupus Clinic Cohort [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/anifrolumab-long-term-treatment-is-more-effective-against-organ-damage-than-standard-of-care-alone-results-from-an-external-control-arm-study-on-organ-damage-in-phase-3-clinical-trials-and-the-univer/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anifrolumab-long-term-treatment-is-more-effective-against-organ-damage-than-standard-of-care-alone-results-from-an-external-control-arm-study-on-organ-damage-in-phase-3-clinical-trials-and-the-univer/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology